COMPARISON OF THE EFFECTS OF ANTIDEPRESSANTS ON COGNITION FUNCTIONS IN PATIENTS OF MAJOR DEPRESSIVE DISORDERS IN TERTIARY CARE HOSPITAL IN HARYANA

SEEMA RANI; NITIKA SINDHU; RAHUL SAINI; A.K PANDEY; ARVIND NARWAT; SUNNY GARG

doi:10.22159/ajpcr.2021.v14i3.40467

Authors

SEEMA RANI Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India.
NITIKA SINDHU Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India.
RAHUL SAINI Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India.
A.K PANDEY Department of Psychiatry, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India.
ARVIND NARWAT Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India.
SUNNY GARG Department of Psychiatry, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i3.40467

Keywords:

Hamilton depression rating scale, Montreal cognitive assessment scale, Fluoxetine and venlafaxine

Abstract

Objective: Depression is one of the most common mood disorders. Patients with major depressive disorder (MDD) usually present alterations in various cognitive functions. Several cost-effective interventions have shown favorable recovery and positive outcomes in the care and management of depression. The objective of the study was to compare the effect of fluoxetine (selective serotonin reuptake inhibitors), and venlafaxine (serotonin-norepinephrine reuptake inhibitors) on cognitive functioning in patients with MDD.

Methods: This prospective, single-blinded, randomized, and comparative interventional clinical study was conducted in a tertiary care hospital in Haryana. Fifty-two patients of MDD (ICD-10) were randomly divided into two groups: Group F and Group V, allocated to receive fluoxetine and venlafaxine, respectively. The assessment was done during the enrolment and at the end of the 3rd, 6th, 9th, and 12th weeks of treatment using the ABC-Hamilton Depression Rating Scale (HAM-D) and Montreal Cognitive Assessment (MoCA) Scale.

Statistical Analysis Used: The intragroup analysis was performed using repeated measures ANOVA while intergroup analysis was performed using unpaired “t”-test. p<0.05 was considered statistically significant.

Results: Mean HAM-D score was clinically as well as statistically significant at the end of the 12th week of treatment as compared to baseline in both the groups while on the intergroup comparison, there was no statistically significant difference in both groups. The mean MoCA score was (25±2.19) in Group F and (23.76±6.97) in Group V at the end of the 12th week. On intergroup analysis at the 12th week, a statistically significant improvement in cognitive functions was observed in patients Group F as compared to Group V (p<0.05).

Conclusions: The study of fluoxetine comparatively better improves cognition functions as compared to venlafaxine.

Downloads

Download data is not yet available.

References

James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1789-858.

Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: Possible implications for functional neuropathology. Br J Psychiatry 2001;178:200.

Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K, et al. Executive and prefrontal dysfunction in unipolar depression: A review of neuropsychological and imaging evidence. Neurosci Res 2004;50:1-11.

Saxena S, Krug E, editors. Preventing Suicide: A Global Imperative. Geneva: World Health Organization; 2014. p. 1-92.

World Health Organisation. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Geneva: World Health Organization; 2016.

O’Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In: Brunton LL, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. New York: ???; ???. p. 397-415.

World Health Organisation. International Classification of Diseases (ICD) 10. Depressive Episode. Geneva: World Health Organisation; F32.9.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.

Nasreddine ZS, Phillips NA, Bedirian V. The montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-9.

Ghodke VB, Mohanty IR, Ghildiyal R, Shounak A, Deshmukh YA, et al. Effect of selective serotonin reuptake inhibitors on psychomotor function in patients of depression: A comparative study of sertraline and fluoxetine. J Med Sci 2015;2:72-7.

Jaykaran, Bhardwaj P, Kantharia N D, Yadav P, Panwar A. Effect of fluoxetine on some cognitive functions of patients of depression. Indian J Psychol Med 2009;31:24-9.

Mendhe PP, Shah SP, Desai MK, Parikh MN. Comparison of effect of antidepressants on psychomotor functions. Indian J Psychol Med 2017;39:69-75.

Wagner S, Helmreich I, Wollschlager D, Meyer K, Kaaden S, Reiff J, et al. Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with major depressive disorder. PLoS One 2018;13:1-13.

Ixchel HG, Esteve GF, Daniel HG, Joan GO, Erika HC, Jorge EH. Effects of selective serotonin reuptake and dual serotonergic– noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatric Res 2009;43:855-63.

Chang HH, Lee IH, Gean PW, Lee SY, Chi MH, Yang YK, et al. Treatment response and cognitive impairment in major depression: Association with C-reactive protein. Brain Behav Immun 2012;26:90-5.

Halahakoon DC, Roiser JP. Cognitive impairment in depression and its (non-)response to antidepressant treatment. Evid Based Mental Health 2016;19:e23.

Shilyansky C, Williams LM, Gyurak A. Effect of antidepressant treatment on cognitive impairments associated with depression: A randomised longitudinal study. Lancet Psychiatry 2016;3:425-35.

Folstein MF, Folstein SE, McHugh PR. “Mini-mentalstate” a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;2:189-98.

Donovan M, Mario C, Laurie G, Susan R, Chris T, Michael ET. Psychiatric rating scales. Handb Clin Neurol 2012;106:227-37.

Blair M, Coleman K, Jesso S, Jodoin VD, Smolewska K, Warriner E, et al. Depressive symptoms negatively impact montreal cognitive assessment performance: A memory clinic experience. Can J Neurol Sci 2016;43:513-7.

Mendhe PP, Shah SP, Desai MK, Parikh MN. Comparison of effect of antidepressants on psychomotor functions. Indian J Psychol Med 2017;39:69-75.